## CITATION REPORT List of articles citing

Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1)

DOI: 10.7326/m20-1998 Annals of Internal Medicine, 2020, 173, 137-142.

Source: https://exaly.com/paper-pdf/75749851/citation-report.pdf

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
24	Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, W88-W89	8	9
23	Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, W48-W51	8	8
22	Correction: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19?. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 166	8	
21	Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 287-296	8	129
20	Chloroquine and COVID-19: Should We Care about Ototoxicity?. <i>International Archives of Otorhinolaryngology</i> , <b>2020</b> , 24, e359-e363	1.5	2
19	Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	26
18	Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter. <i>Postgraduate Medical Journal</i> , <b>2021</b> , 97, 676-677	2	7
17	A Case Report of COVID-19 in New Orleans, Louisiana: Highlighting the Complexities of Prognostication in a Critically Ill Patient. <i>Palliative Medicine Reports</i> , <b>2020</b> , 1, 227-231	1	1
16	Covid-19 and autoimmunity. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102597	13.6	248
15	Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. <i>Emerging Microbes and Infections</i> , <b>2020</b> , 9, 1397-1406	18.9	31
14	Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 36, 101812	8.4	12
13	Pharmacotherapics Advice in Guidelines for COVID-19. Frontiers in Pharmacology, 2020, 11, 950	5.6	6
12	Developing trustworthy recommendations as part of an urgent response (1-2 weeks): a GRADE concept paper. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 129, 1-11	5.7	14
11	Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 30-42	5.1	70
10	Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2021</b> , 376, 261-272	4.7	2
9	Critical Review of the Scientific Evidence and Recommendations in COVID-19 Management Guidelines. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab376	1	3
8			

## CITATION REPORT

7	Utility of hydroxychloroquine for COVID-19: Are we hoping against hope?. <i>Indian Journal of Rheumatology</i> , <b>2021</b> , 16, 229	0.5		
6	Reply to letter to editor by McCullough. <i>Annals of Medicine</i> , <b>2021</b> , 53, 335-336	1.5		
5	Potential SARS-CoV-2 3CLpro inhibitors from chromene, flavonoid and hydroxamic acid compound based on FRET assay, docking and pharmacophore studies. <i>Results in Chemistry</i> , <b>2021</b> , 3, 100195	2.1	4	
4	I. Cloroquina / hidroxicloroquina y azitromicina. Revisilī narrativa de seguridad. <b>2020</b> , 2, 71-82			
3	COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. Postepy Mikrobiologii, <b>2020</b> , 59, 207-	· <b>225</b> 0.4	О	
2	Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India. <i>Journal of Public Health Research</i> , <b>2020</b> , 9, 1888	2.2		
1	Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-Igo-goRelated Gene and Cav1.2. <i>Frontiers in Pharmacology</i> , 13,	5.6		